Every GLP Research Hub submission tagged to endpoint, ranked by score. Discussed in 1 community.
unpopular opinion: most of what gets said here about hazard ratio is guesswork, which sounds obvious until you try to state the evidence for it. Went looking for the…
SELECT: what the trials say vs what this community says — a position I have arrived at slowly and would like tested. Why comparing across trials almost never works,…
write the concentration on the vial. that is the whole post. Two minutes of reading now saves an argument later. Quoted a figure here confidently, got asked whether it…
hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsproposal — a flair for FLOW posts, and it will stay as it is unless somebody makes the case to change it. Open-label extensions lose their randomisation. Anybody still…
Asking properly rather than in a comment on somebody else’s thread: does SELECT actually matter or is it forum lore at this point. Compared myself to a trial mean for…
Trying to get a straight answer on this: help me understand SURMOUNT, I have read the wiki twice. Relative risk reduction without the baseline rate is uninterpretable.…
Asking properly rather than in a comment on somebody else’s thread: does SELECT actually matter or is it forum lore at this point. Compared myself to a trial mean for…
The title is the whole question — genuine question about TRIUMPH that I am slightly embarrassed to ask — but here is why I am asking. Discontinuation rates are a…
SURPASS — 9 things I got wrong before I got it right. Change my mind, genuinely — I have no stake in being right about this. Started keeping the trial identifiers…
The title is the argument: reading SURMOUNT threads from 2024 and half of it aged badly. Here is the rest of it. Discontinuation rates are a tolerability result. A…
SURPASS — 11 things I got wrong before I got it right. It is the sort of thing everyone half-believes and nobody writes down. A confidence interval is the range of…
The title is the argument: SURPASS — 15 things I got wrong before I got it right. Here is the rest of it. Discontinuation rates are a tolerability result. A trial with…
reading SURMOUNT threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments. Quoted a figure here confidently,…
Asking properly rather than in a comment on somebody else’s thread: how much of what we believe about endpoint actually comes from hazard ratio threads. Why comparing…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsThinking out loud about this: the endpoint advice in here is 3 years out of date. 3 years — those are the numbers, and they are the ones I am willing to defend.…
hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline…
how much of what we believe about endpoint actually comes from TRIUMPH threads. I would rather ask a basic question now than get this wrong quietly for two months.…
Trying to get a straight answer on this: genuine question about TRIUMPH that I am slightly embarrassed to ask. Why comparing across trials almost never works, with the…
Thinking out loud about this: SURPASS — 12 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing…
SURPASS — 4 things I got wrong before I got it right. Change my mind, genuinely — I have no stake in being right about this. The registered protocol is public.…
the FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open. The discontinuation numbers…
how do you actually verify SURPASS. I would rather ask a basic question now than get this wrong quietly for two months. The discontinuation numbers were the most useful…
Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Compared myself to a trial mean for about six months before…
Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Relative risk reduction without the baseline rate is…
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference